Literature DB >> 25580892

A Survey on the Preference of Sustained Glaucoma Drug Delivery Systems by Singaporean Chinese Patients: A Comparison Between Subconjunctival, Intracameral, and Punctal Plug Routes.

Hiok Hong Chan1, Tina T Wong, Ecosse Lamoureux, Shamira Perera.   

Abstract

PURPOSE: To investigate the acceptance and preferences rates of 3 sustained drug delivery systems in glaucoma patients.
MATERIALS AND METHODS: A cross-sectional study involving 250 Chinese patients recruited from outpatient glaucoma clinics in Singapore using an interviewer-administered survey. Beliefs toward medicines, eye drops, illness perception, medication adherence, and health literacy were assessed using validated questionnaires. After receiving standard information on the 3 sustained drug delivery systems, that is, subconjunctival, intracameral, and punctal routes; each route's acceptance and attitudes were determined.
RESULTS: The subconjunctival (acceptance: 61.6%, n=154), intracameral (acceptance: 57.2%, n=143), and punctal (acceptance: 63.2%, n=158) routes were willing to be accepted by the majority of the interviewed patients. Among those, 78.6%, 79.1%, and 78.5% were willing to pay an equal or higher cost compared with their current eye drops for the subconjunctival, intracameral, and punctal plug routes, respectively. Independent factors associated with the acceptance for subconjunctival, intracameral, and punctal plug routes included: male sex (P=0.007, 0.014, 0.046, respectively), patients not on health care subsidies (P=0.022, 0.002, 0.016, respectively), and bilateral glaucoma disease (P=0.003, 0.013, 0.004, respectively). A total of 120 (48.0%) patients ranked punctal plug placement as the preferred route for sustained drug delivery followed by subconjunctival (n=76, 30.4%) and intracameral (n=54, 21.6%) routes.
CONCLUSIONS: Sustained drug delivery for the medical treatment of glaucoma is an acceptable alternative to daily eye drop administration by most Singaporean Chinese individuals in this study. Male patients, nonsubsidized patients, and those with bilateral glaucoma were independently associated with preference of these 3 alternative routes of administration to traditional glaucoma drops.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25580892     DOI: 10.1097/IJG.0000000000000197

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  4 in total

1.  Patient attitudes toward novel glaucoma drug delivery approaches.

Authors:  Benjamin B Wang; Michael M Lin; Thuan Nguyen; Angela V Turalba
Journal:  Digit J Ophthalmol       Date:  2018-09-30

2.  Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent.

Authors:  Jean Kim; Max Kudisch; Nina Rosa Konichi da Silva; Hiroyuki Asada; Eri Aya-Shibuya; Michele M Bloomer; Sri Mudumba; Robert B Bhisitkul; Tejal A Desai
Journal:  J Control Release       Date:  2017-11-07       Impact factor: 9.776

3.  Vision-related quality of life in patients with glaucoma: the role of illness perceptions.

Authors:  Qiqi Zhang; Wenzhe Zhou; Di Song; Yanqian Xie; Hao Lin; Youping Liang; Yanhan Ren; Yuanbo Liang; Yanyan Chen
Journal:  Health Qual Life Outcomes       Date:  2022-05-12       Impact factor: 3.077

4.  Long Term Glaucoma Drug Delivery Using a Topically Retained Gel/Microsphere Eye Drop.

Authors:  Morgan V Fedorchak; Ian P Conner; Joel S Schuman; Anthony Cugini; Steven R Little
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.